News & Updates

In a real-world cohort of patients with highly refractory Crohn’s disease (CD), upadacitinib treatment prompted clinical response in most and steroid-free clinical remission in half, while having an acceptable safety profile.

Among patients with gastric cancer and peritoneal metastasis, treatment with neoadjuvant intraperitoneal–systemic (NIPS) regimen, which consists of intraperitoneal (IP) and intravenous (IV) paclitaxel plus S-1, significantly improved overall survival (OS) compared with IV paclitaxel plus S-1 only (PS regimen), according to the DRAGON-01 trial presented at ASCO GI 2025.

In children and adolescents who have contracted COVID-19, gastrointestinal (GI) tract symptoms may remain for up to 2 years, as reported in a large retrospective study.

New drug applications approved by US FDA as of 1-15 February 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

The attainment of remission in EGPA is durable whether treated with benralizumab for 2 years or switched to benralizumab after 52 weeks of mepolizumab treatment, with additional merits observed among those who switched, as indicated in the OLE of MANDARA

The combination of nivolumab and ipilimumab (NIVO + IPI) significantly improves overall survival (OS) and objective response rate (ORR) compared with lenvatinib or sorafenib (LEN/SOR) in the first-line setting for patients with unresectable hepatocellular carcinoma (uHCC), based on the CheckMate 9DW expanded analyses presented at ASCO GI 2025.

Treatment with Janus kinase (JAK) inhibitors, particularly tofacitinib and upadacitinib, was associated with high rates of clinical, endoscopic, and histologic remission in older adults with moderate-to-severe inflammatory bowel disease (IBD), according to a study presented at CCC 2025.